Skip to main content
Premium Trial:

Request an Annual Quote

Applied BioCode Raises $13.2M in Public Stock Offering

NEW YORK (GenomeWeb) – Applied BioCode announced today that it has secured $13.2 million through a public offering of its common stock.

In addition, the firm said it has also secured $8 million in total credit lines extended from an undisclosed FDIC-insured financial institution and a commercial lender.

Applied BioCode obtained US Food and Drug Administration clearance earlier this month for its MDx-3000 molecular diagnostics system along with a multiplex panel assay that tests for 17 gastrointestinal pathogens. The firm, which is a registered Cayman Islands corporation with facilities in the US and Taiwan, plans to use the new funds to commercialize the Gastrointestinal Pathogen Panel (GPP) and MDx-3000 in the US, noting in a statement that the system "will provide high-volume laboratories with an alternative to high-cost cartridge-based systems."

The GPP is the first test in a menu of multiplex infectious disease test panels that Applied BioCode will bring to market on the MDx-3000 system, the company added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.